BRCA1 and endometrial cancer: Subsequent studies identified a larger risk for those women taking tamoxifen compared to those without, and conflicting results have been obtained whether there is any tamoxifen-independent residual risk of endometrial cancer for carriers of a pathogenic BRCA1 or BRCA2 variant [82,83].